GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inovio Pharmaceuticals Inc (NAS:INO) » Definitions » Cyclically Adjusted Revenue per Share

Inovio Pharmaceuticals (Inovio Pharmaceuticals) Cyclically Adjusted Revenue per Share : $3.38 (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Inovio Pharmaceuticals Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Inovio Pharmaceuticals's adjusted revenue per share for the three months ended in Dec. 2023 was $0.005. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $3.38 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Inovio Pharmaceuticals's average Cyclically Adjusted Revenue Growth Rate was -8.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -5.00% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Inovio Pharmaceuticals was 4.40% per year. The lowest was -37.50% per year. And the median was -4.20% per year.

As of today (2024-05-16), Inovio Pharmaceuticals's current stock price is $13.07. Inovio Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $3.38. Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio of today is 3.87.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Inovio Pharmaceuticals was 90.39. The lowest was 1.21. And the median was 17.28.


Inovio Pharmaceuticals Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Inovio Pharmaceuticals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inovio Pharmaceuticals Cyclically Adjusted Revenue per Share Chart

Inovio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.03 3.80 3.61 3.70 3.38

Inovio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.70 3.71 3.72 3.45 3.38

Competitive Comparison of Inovio Pharmaceuticals's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Inovio Pharmaceuticals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inovio Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.005/129.4194*129.4194
=0.005

Current CPI (Dec. 2023) = 129.4194.

Inovio Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.513 99.695 0.666
201406 0.754 100.560 0.970
201409 0.364 100.428 0.469
201412 0.485 99.070 0.634
201503 1.018 99.621 1.323
201506 0.935 100.684 1.202
201509 3.924 100.392 5.059
201512 0.984 99.792 1.276
201603 1.347 100.470 1.735
201606 1.020 101.688 1.298
201609 2.039 101.861 2.591
201612 1.379 101.863 1.752
201703 1.676 102.862 2.109
201706 3.248 103.349 4.067
201709 0.364 104.136 0.452
201712 1.165 104.011 1.450
201803 0.203 105.290 0.250
201806 3.216 106.317 3.915
201809 0.260 106.507 0.316
201812 0.313 105.998 0.382
201903 0.348 107.251 0.420
201906 0.017 108.070 0.020
201909 0.101 108.329 0.121
201912 0.033 108.420 0.039
202003 0.128 108.902 0.152
202006 0.021 108.767 0.025
202009 0.016 109.815 0.019
202012 0.384 109.897 0.452
202103 0.022 111.754 0.025
202106 0.016 114.631 0.018
202109 0.017 115.734 0.019
202112 0.047 117.630 0.052
202203 0.011 121.301 0.012
202206 0.040 125.017 0.041
202209 0.441 125.227 0.456
202212 0.006 125.222 0.006
202303 0.005 127.348 0.005
202306 0.010 128.729 0.010
202309 0.017 129.860 0.017
202312 0.005 129.419 0.005

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Inovio Pharmaceuticals  (NAS:INO) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Inovio Pharmaceuticals's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=13.07/3.38
=3.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Inovio Pharmaceuticals was 90.39. The lowest was 1.21. And the median was 17.28.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Inovio Pharmaceuticals Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Inovio Pharmaceuticals's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Inovio Pharmaceuticals (Inovio Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
Address
660 West Germantown Pike, Suite 110, Plymouth Meeting, PA, USA, 19462
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Executives
Lota S. Zoth director 334 CR 692, BUFFALO GAP TX 79508
David B. Weiner director 717 BEACOM LANE, MERION STATION PA 19066-1603
Simon X Benito director 967 LAWRENCE AVE, WESTFIELD NJ 07090
Michael John Sumner officer: Chief Medical Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Laurent Humeau officer: Chief Scientific Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jacqueline Elizabeth Shea officer: Chief Operating Officer C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Peter Kies officer: CFO
Roger D Dansey director 21823 30TH DRIVE SE, BOTHELL WA 98021
Jong Joseph Kim director, officer: Chief Executive Officer 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Jay Shepard director 15977 GRANDVIEW AVENUE, MONTE SERENO CA 95030
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Wendy L Yarno director
Morton Collins director
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Niranjan Sardesai officer: Chief Operating Officer VGX PHARMACEUTICALS, INC., 450 SENTRY PARKWAY, BLUE BELL PA 19422